美国州强制保险覆盖与胚胎植入前遗传学检测
该回顾性队列研究分析2014至2016年向美国辅助生殖技术协会报告的301465个体外受精周期,发现胚胎植入前遗传学检测使用比例从2014年17%升至2016年34%,主要由非整倍体检测驱动;有保险强制覆盖的州该检测使用风险比为0.69,选择性性别选择使用风险比为0.44,均低于无强制覆盖州。
要点
- 体外受精周期中使用胚胎植入前遗传学检测的比例从2014年17%上升至2016年34%。
- 有保险强制覆盖的州胚胎植入前遗传学检测使用风险比为0.69(95%CI 0.67-0.71,P<.001),低于无强制覆盖州。
- 有保险强制覆盖的州选择性性别选择检测风险比为0.44(95%CI 0.36-0.53,P<.001),低于无强制覆盖州。
核心结论
- 美国体外受精周期中胚胎植入前遗传学检测的使用比例正在增加,且在体外受精主要自费的州最高。
- 非医学性别选择的胚胎植入前遗传学检测在体外受精自费的州也更常见,且更可能产生男性后代。
- 对这些趋势的持续监测很重要,因为这些做法存在争议,并可能对未来人口结构产生影响。
研究设计与样本
- 该研究为回顾性队列研究,分析了2014年至2016年间向美国辅助生殖技术协会报告的301465个体外受精周期。
- 采用二项逻辑回归分析州强制保险覆盖与胚胎植入前遗传学检测使用之间的关联。
- 使用每位患者首次成功周期的新生儿性别计算性别比,并按州强制保险覆盖和选择性性别选择的胚胎植入前遗传学检测指征进行比较。
主要发现
- 体外受精周期中使用胚胎植入前遗传学检测的比例从2014年的17%上升至2016年的34%,此增加主要由非整倍体检测驱动。
- 有保险强制覆盖的州相比无强制覆盖的州,进行胚胎植入前遗传学检测的可能性更低(风险比0.69,95%CI 0.67-0.71,P<.001)。
- 有保险强制覆盖的州相比无强制覆盖的州,因选择性性别选择而进行胚胎植入前遗传学检测的可能性也更低(风险比0.44,95%CI 0.36-0.53,P<.001)。
- 在活产新生儿中,任何指征的胚胎植入前遗传学检测周期的男/女性别比为115,高于无胚胎植入前遗传学检测周期的105(P<.001)。
- 专门因选择性性别选择而进行胚胎植入前遗传学检测的男/女性别比为164,高于其他指征的112(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association between state-mandated insurance coverage for infertility treatment in the United States and the utilization of and indication for preimplantation genetic testing. METHODS: This was a retrospective cohort study of 301,465 in vitro fertilization (IVF) cycles reported to the Society for Assisted Reproductive Technology between 2014 and 2016. Binomial logistic regression was performed to examine associations between state-mandated insurance coverage and preimplantation genetic testing use. The neonate's sex from each patient's first successful cycle was used to calculate sex ratios. Sex ratios then were compared by state mandates and preimplantation genetic testing indication for elective sex selection. RESULTS: The proportion of IVF cycles using preimplantation genetic testing increased from 17% in 2014 to 34% in 2016. This increase was driven largely by preimplantation genetic testing for aneuploidy testing. Preimplantation genetic testing was less likely to be performed in states with mandates for insurance coverage than in those without mandates (risk ratio [RR] 0.69, 95% CI 0.67-0.71, P<.001). Preimplantation genetic testing use for elective sex selection was also less likely to be performed in states with mandates (RR 0.44, 95% CI 0.36-0.53, P<.001). Among liveborn neonates, the male/female sex ratio was higher for IVF cycles with preimplantation genetic testing for any indication (115) than for those without preimplantation genetic testing (105) (P<.001), and the use of preimplantation genetic testing specifically for elective sex selection had a substantially higher (164) male/female sex ratio than preimplantation genetic testing for other indications (112) (P<.001). CONCLUSION: The proportion of IVF cycles using preimplantation genetic testing in the United States is increasing and is highest in states where IVF is largely self-funded. Preimplantation genetic testing for nonmedical sex selection is also more common in states where IVF is self-funded and is more likely to result in male offspring. Continued surveillance of these trends is important, because these practices are controversial and could have implications for future population demographics.
引用
- Bedrick BS, Tipping AD, Nickel KB, et al. State-Mandated Insurance Coverage and Preimplantation Genetic Testing in the United States. Obstet Gynecol. 2022. PMID: 35271533. doi:10.1097/AOG.0000000000004712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。